Angiex, Inc.
- | Biotech or pharma, therapeutic R&D
- | Biotech or pharma, animal health
Angiex has developed a new class of drug, Nuclear-Delivered Antibody-Drug Conjugates, which release payloads directly into nucleus or cytosol for exceptional efficacy and therapeutic margin. Angiex's lead drug, AGX101, a TM4SF1-directed microtubule inhibitor antibody-drug conjugate for therapy of solid cancers, is in Phase 1 trials for all solid cancers.
Address
CambridgeMA
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}